The National Institutes of Health (NIH) has recognized the Syn-One Test as one of its “Top Promising Medical Findings for 2024”. The skin-biopsy test is the first commercially available test of its kind that can detect phosphorylated alpha-synuclein (P-SYN), a protein indicative of Parkinson’s disease (PD) and related synucleinopathies, including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF).
In March 2024, the breakthrough results of the Synuclein-One Study, which support Syn-One as a reliable diagnostic tool for synucleinopathies, were published in the Journal of the American Medical Association (JAMA). In the blinded, multicenter study, which included 428 participants, the test detected P-SYN in 92.7% of those with clinically diagnosed PD, 98.2% of those with MSA, 96.0% of those with DLB, and 100% of those with PAF. Only 3.3% of healthy controls had P-SYN, demonstrating a 96.7% specificity rate for Syn-One. Researchers also observed a correlation between P-SYN levels and disease severity, indicating the tests potential to not only aid in diagnosis but also to monitor disease progression.
CND is honored to have the Syn-One Test and its supporting research recognized by the NIH.
See the NIH’s full list of Promising Medical Findings in 2024
Learn more about the Syn-One Test®
Follow CND Life Sciences on LinkedIn